Pancreatic cancer could be treated with a Parkinson's drug

 

Bhutia Lab

A new study shows that a common drug for Parkinson's disease has anti-cancer effects in mice and human pancreatic cells.

The new research suggests that carbidopa, which is a drug approved by the Food and Drug Administration (FDA) and widely used to treat Parkinson's disease, has significant anti-cancer properties.

Carbidopa is typically used in conjunction with levodopa (L-Dopa) to treat Parkinson's disease. And previous studies have shown that patients with Parkinson's tend to have a lower incidence of cancer.

In older research, scientists investigated whether or not it was the drug L-Dopa that yielded the anti-cancer effect, but they did not find any significant results.

So now, a team led by Dr. Yangzom Bhutia - from the Texas Tech University Health Sciences Center (TTUHSC) in Lubbock - hypothesized that carbidopa alone could have anti-cancer properties.

Commenting on the motivation for the research, Dr. Bhutia says, "Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon."

"Carbidopa is never used by itself as a drug for any disease," she adds. "But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."

The first author of the study is Jiro Ogura, of the Department of Cell Biology and Biochemistry at TTUHSC, and the findings were published in the Biochemical Journal.

Article originally published in Medical News Today, www.medicalnewstoday.com

To read full article, please visit https://www.medicalnewstoday.com/articles/319578.php

Related Stories

Noise-Induced Hearing Loss in Rural Adolescents

Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.

Willed Body Memorial Service Honors Those Who Donated

On Memorial Day each May, a service is conducted at the Texas Tech University Health Sciences Center Institute of Anatomical Sciences to pay respect to the Willed Body Program donors and their families.

Molecular Pathology Preceptorship: Unmatched Value and Experience

Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.

Recent Stories

Education

Texas Tech University Health Sciences Center Earns SACSCOC Recognition

TTUHSC has received a clean bill of health from the regional accrediting body, the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), following a Fifth-Year Interim Review by a committee from peer institutions.

Noise-Induced Hearing Loss in Rural Adolescents

Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.

Research

TTUHSC Amarillo Awarded $50,000 Grant for Cutting-Edge Cancer Research

TTUHSC in Amarillo has received a $50,000 grant from the Harrington Cancer and Health Foundation to support groundbreaking cancer research led by Hiranmoy Das, Ph.D.